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Abstract: Nearly 6000 solid organ transplants have been performed at 
the University of Pittsburgh since 1981. Posttransplant lymphoproliferative 
disorders (PTLD) have occurred in 131 patients, at a frequency of 2.2%. 
The majority of cases manifest within 6 months following allograft, but 
individual lesions may arise several years thereafter. From 1981 to 1989, 
cyclosporine-A (CsA) served as the primary immunosuppressant in this 
population. In March of 1989, FKS06 was introduced for clinical trials. 
Since that time, 1421 patients have received FKS06 either for primary 
immunosuppression or as rescue therapy. The frequency of PTLD in this 
subpopulation is I.S%. PTLD arising under FKS06-containing regimens 
have clinicopathologic features similar to those arising with CsA immuno-
suppression. The frequency of PTLD at this point in time is approxi-
mately 1% in kidney allograft patients, 2.7% in liver, 3.3% in heart and 
3.8% in heart/lung or lung recipients. An understanding of the range of 
histologic appearance is important for the diagnosis of PTLD, especially 
when it involves the allograft itself. Immunoglobulin heavy chain gene 
analysis shows that lesions with no rearrangements or with a rearrange-
ment in only a small proportion of cells are more likely to respond to 
reduced immunosuppression than are those with clonal rearrangement 
involving a high proportion of cells. However, this distinction is not abso-
lute, and a trial of reduced immunosuppression appears to be indicated 
regardless of clonal status. 
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Introduction 
Lymphomas and lymphoproliferative disorders 
arise in a small but significant minority of organ 
allograft recipients (1). Penn's analysis of over 5000 
neoplasms arising in transplant patients has pro-
vided a framework for understanding this phenom-
enon (2). Post-transplant lymphoid tumors are 
most often of B-cell origin and they are frequently 
preceded by infection with the Epstein-Barr virus. 
The lesions tend to be extranodal, may involve the 
allograft organ and may occur within a short time 
after transplantation. The opportunistic nature of 
this disorder has been underscored by the well-
described phenomenon of tumor regression follow-
ing a reduction of immunosuppression (1). Ap-
proximately 15% of tumors are ofnon-B cell origin, 
raising additional questions regarding the etiology, 
pathogenesis and behavior of this category of 
lesions (2). 
This work was supported by the Pathology Education and 
Research Foundation, Pittsburgh PA, and by NIH Grant 5 
POI CA 47445-02. 
Despite the recent rapid strides in our under-
standing of this disease, much remains to be 
learned. Although primary EBV infection, heavy 
immunosuppression, and type of allograft have all 
been identified as relative risk factors for develop-
ment of posttransplant lymphoproliferative dis-
orders (PTLD), there is no way to predict who will 
and who will not develop such a disorder. Although 
many PTLD respond to a reduction of immuno-
suppression, there are no precise pathologic criteria 
to diagnose those lesions which progress under 
this regimen. The continuing evolution of clinical 
immunosuppression and of new transplantation 
procedures requires constant surveillance of un-
toward side-effects, including lymphomas. The re-
lationship of PTLD to conventional lymphoma is 
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only beginning to be understood, and no adequate 
hypothesis yet exists to guide a therapeutic ap-
proach to EBV-negative, non-B celllymphoproli-
ferations in this population. 
Our current state of knowledge mandates an 
open exchange of information regarding individual 
experience in the diagnosis and treatment of this 
life-threatening but potentially curable condition. 
This report updates features of PTLD as seen in 
the transplant patient population at the University 
of Pittsburgh. 
Patients and methods 
Patients 
The organ transplant program at the University of 
Pittsburgh Medical Center was initiated in 1981. 
As of May 1991, a total of 3019 liver, 2057 renal, 
583 heart, 79 heart/lung, and 51 lung transplant 
procedures had been performed. In addition, 79 
procedures had involved the allograft of liver and 
other organs, and several had involved multiviscer-
al transplants (liver, pancreas, bowel). The multi-
visceral transplant procedure has been modified 
into a cluster operation in which liver, a small 
portion of bowel, and pancreatic islets are trans-
planted. As of December 1990, a single small bowel 
transplant had been performed. Thus, a total of 
5873 transplant procedures were performed during 
this period. The retransplant frequency for liver 
and kidney is less than 10%, and that for thoracic 
transplant recipients is essentially nil. Bone marrow 
transplants are performed at a separate institute 
and are not considered in this report. The figures 
are derived from the Transplant Database, which 
is maintained and continuously updated within the 
Division of Transplantation Surgery. 
Immunosuppression 
From 1981 to 1989, cyclosporine-A (CsA) was the 
primary immunosuppressant used in all organ 
transplant groups at the University of Pittsburgh. 
In March 1989 the macrolide immunosuppressant 
FK506 was introduced for human use (3). As of 
May 1991, a total of 1421 patients had received 
FK506, either as primary immunosuppression or 
as rescue therapy. Prophylactic OKT3 or RATG 
was utilized in cardiothoracic transplants until Oc-
tober 1989, and was discontinued when FK506 
therapy was initiated in this group. 
Diagnosis of lymphomas and Iymphoproliferative disorders 
The diagnosis of post-transplant lymphoprolifera-
tive disorder (PTLD) is used at our facility to refer 
to the entire spectrum of atypicallymphoprolifera-
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tions arising within the organ transplant popula-
tion. PTLD are subdivided into polymorphic and 
monomorphic subtypes on the basis of histologic 
appearance (1). Further evaluation includes pheno-
typic and genotypic analysis of clonal status, DNA 
analysis for the presence of EBV and for study of 
the clonal status of EBY, as previously described 
(3). A total of 133 patients received the diagnosis of 
PTLD or lymphoma during the period 1981-May 1 
1991 at the University of Pittsburgh. Two patients 
had been previously transplanted at the University 
of Colorado and are excluded from this study. 
Results 
1. Frequency of PTLD development and influence of allograft 
The 131 cases of PTLD constitute approximately 
2.2% of the transplant population for this period. 
The annual frequency has remained relatively con-
stant, ranging from 0.7% to 3.4% per yr. No trends 
of increased or decreased frequency have been un-
covered during this time interval. 
To date, 83 PTLDs have been identified in liver 
allograft recipients, for an approximate frequency 
of 2.7%. Two cases of PTLD have occurred when 
livers have been transplanted in association with 
other organs (2.5%). Heart allograft recipients have 
a 3.3% incidence of PTLD (19 cases) whereas 
heart/lung recipients and lung recipients as a group 
have an incidence of 3.8% (5 cases). Following the 
occurrence of PTLD in 2 patients who underwent 
multivisceral transplantation, this operation has 
been discontinued. PTLD has not complicated the 
course of any patient who underwent intestinal 
transplantation, including those transplanted out-
side of the study interval. 
2. Influence of immunosuppressive medication 
FK506 was introduced into clinical use at the Uni-
versity of Pittsburgh in March, 1989. Since that 
time, 1421 patients have been immunosuppressed 
with this drug. There have been 16 cases of PTLD 
occurring in patients primarily immunosuppressed 
with FK506, and 5 cases of PTLD in patients who 
were switched to FK following CsA immunosup-
pression. Thus, 21 of 1421 patients, or 1.6%, have 
developed PTLD while on FK506 immunosuppres-
sion. Eight additional patients were switched to 
FK506 at varying times following the diagnosis of 
CsA-associated PTLD. None of these patients has 
developed recurrent PTLD to date. 
3. Influence of OKT3 
Twenty-five of the 131 PTLD patients (19%) re-
ceived OKT3 at some time during their course. 
---.----------
Data regarding the entire population of patients 
who received OKT3 are currently being collected 
and will form the basis of a subsequent report. 
4. Time of onset of PTLD 
The majority of cases continue to occur within 6 
months following transplantation. The mean time 
to tumor onset in the sUbpopulation of patients 
treated with FK506 was 4 months. The mean time 
of onset for PTLD in association with CsA in this 
group has been calculated at 6.4 months, with a 
median of 4.4 months (4). The time of onset for 
the entire PTLD population ranges from 0.7 to 162 
months. 
5. Pathology studies of PTLD 
Lesions demonstrate the range of histopathology 
as previously described (4). Results of immuno-
globulin heavy chain gene rearrangement analysis 
have been graded 0-3+ in 48 specimens to date 
(see Methods Section). Of these 48, 35% have been 
nonclonal (polyclonal), 19% have had minor 
(1 +) rearranged subpopulations, 33% have had 
more significant percentages of rearranged cells 
within the lesions, and l3% appear to have been 
composed almost entirely of clonal outgrowths of 
cells. In 2 cases in which Ig gene rearrangement 
studies were nonclonal, subsequent analysis of the 
terminal repeat region of EBV revealed a clonal 
pattern. 
6. Treatment of PTLD 
Reduction of immunosuppression combined with 
acyclovir and surgery for symptomatic lesions con-
tinues to be employed in all patients following the 
diagnosis of PTLD. 
7. Behavior of PTLD 
Current follow-up was available from 62 patients 
for this report. Resolution of PTLD occurred in 
69'% of patients. A somehwat higher rate of res-
olution (81%) was seen in patients who developed 
PTLD in the setting of prior renal transplan-
tation. 
Twenty-five patients with recent follow-up had 
tumor clonality categorized on a 1-3 scale. Of 8 
patients with nonclonal PTLD, resolution was seen 
in 6 (75%). Resolution was observed in all 3 pa-
tients with a I + clonal component. Four of 8 
(50%) patients had resolution when the highest 
grad of clonality was 2 +. In the setting of 3 + 
PTLD, only 2 of 6 (33%) patients showed resol-
ution of disease. 
PTLD in solid organ Tx 
Discussion 
Posttransplant Iymphoproliferative disorder con-
tinues to complicate immunosuppressive regimens 
used for organ transplantation in approximately 
2% of cases. This report indicates that this inci-
dence also occurs in the FK506-containing regimen 
used at our institution. A recent report has gener-
ated concern regarding the incidence of PTLD oc-
curring with the use of prophylactic OKT3 in car-
diac allograft recipients (5). Prophylactic immuno-
suppression with OKT3 has not been used at the 
University of Pittsburgh since late 1989 (6), when 
the use of FK506 was initiated in this allograft 
group. Armitage et ai. have summarized the tho-
racic transplant data prior to that time (mss. in 
preparation). Five of 352 patients (1.4%) who re-
ceived rabbit anti-thymocyte globulin subsequently 
developed PTLD, whereas none of 77 patients who 
received OKT3 developed this disorder. 
The frequency data for individual organ allo-
graft subpopulations show small differences among 
the various groups. However, these differences do 
not appear to be as marked as earlier reports would 
indicate (1). Somewhat higher frequencies may also 
be generated depending upon the method of analy-
sis. For example, if the patients who expire within 
a peri operative period of 30 d are censored from 
analysis, the frequency for lung and heart/lung 
patients rises to 7.9% (Armitage et aI., mss. in 
preparation). In this report, such an approach was 
not taken, since some PTLD arose prior to 30 d. 
The data presented here continue to support 
the hypothesis that PTLD encompasses a range of 
non clonal to clonal proliferations (7). Preliminary 
evidence suggests that there may be some relation-
ship between the extent of rearrangement and the 
ability of the tumor to persist despite a reduction 
of immunosuppression. We cannot advocate using 
the clonal status of these lesions to define treatment 
modalities; at present all patients are given a trial 
of reduced immunosuppression, usually with acy-
clovir. The individual response of the patient must 
be gauged clinically. The fact that patients with a 
clonal component often respond to such treatment 
supports the hypothesis, raised by recent pheno-
typic studies, that PTLD more closely resemble 
EBV-induced lymphoblastoid cells than they do 
fully malignant B lymphocytes of a Burkitt 
lymphoma type (8). 
One concern in reducing immunosuppression as 
part of initial therapy is the fear of graft rejection. 
In renal recipients, loss of the graft is usually pref-
erable to continued growth of the tumor. Histo-
logic rejection is often, but not always, seen in liver 
allografts. In most cases, the graft can be preserved. 
Titration of immunosuppressive dosage may oc-
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casionally be difficult, but is the main option at 
present. Although histologic rejection can be seen 
in heart and heart/lung recipients in such cases, no 
grafts have ever been lost as a result of this ap-
proach (Griffith B., personal communication). 
Our current concepts of EBV -related lympho-
proliferations do not adequately categorize other 
forms of lymphoproliferative disease which may 
occur in this population. One patient not detailed 
in this report had Hodgkin's disease which did 
not respond to reduced immunosuppression. The 
tumor was not related to EBY. The patient remains 
free of disease following radiation therapy. A more 
recent case of non-Hodgkin's lymphoma proved to 
have clonal rearrangement of the T-cell receptor, 
without evidence of EBY. Early follow-up indicates 
that the lesion appears to have regressed following 
reduction of immunosuppression. It is clear that 
the full range of this intriguing group of lesions is 
still being uncovered. Application of the lessons so 
far learned will allow us to identify variant tumors 
that may shed light on mechanisms entirely differ-
ent from those currently thought to be operative 
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